Navigation Links
New Incentives to Help Combat Antimicrobial Resistance, but Overuse of Strong Antibiotics Still Needs to Be Curbed
Date:7/12/2012

ROUND ROCK, Texas, July 12, 2012 /PRNewswire/ -- The FDA Safety Innovation Act (FDASIA), signed yesterday, provides pharmaceutical manufacturers with an extended window of antibiotic formulary exclusivity. This incentive should increase drug innovation, but it doesn't address increasing antimicrobial drug resistance, according to noted expert, Dr. David Khan of The University of Texas Southwestern Medical Center in Dallas.

"Too often, a patient's self-reported penicillin allergy causes broad antibiotics to be prescribed even though penicillin was the most appropriate treatment. However, studies show in nine out of ten cases, patients reporting a penicillin allergy are non-allergic," said Dr. Khan.

"Test before treating with non-penicillin antibiotics. With a simple, quick allergy skin test, doctors can easily and inexpensively determine if penicillin is an option," said Dr. Roland Solensky of the Corvallis Clinic.

"Overuse of broad spectrum antibiotic leads to antimicrobial resistance and the need for more powerful antibiotics, which have more toxic side effects," said Dr. Solensky, who wrote the drug allergy practice guidelines.

"By denying a potentially effective treatment, these patients are susceptible to the overuse of broad spectrum antibiotics, leading to increased drug-resistant bacteria," said Jose A. Moreno Toscano, President of ALK-Abello, Inc.

PRE-PEN® (benzylpenicilloyl polylysine injection USP), a skin test product widely used for more than 30 years, can help medical staff quickly identify patients who can safely receive penicillin, opening up a wider range of options and saving lives in the process.

About ALK
ALK holds worldwide rights to market and distribute PRE-PEN® (benzylpenicilloyl polylysine injection USP) penicillin skin testing product. PRE-PEN® (benzylpenicilloyl polylysine injection USP) is currently approved and sold in the USA and Canada.

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy), a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. The company has approximately 1,400 employees with subsidiaries, production facilities and distributors worldwide. ALK was named one of the Best Companies to Work for in Texas in 2012 by www.BestCompaniesTX.com. Further information is available at www.alk-abello.us.

Contact Information:
Lisa Lawrence
For ALK
512-426-4904
Lisa.Lawrence@hcbhealth.com


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
3. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. UN emission market needs urgent reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, LLC, a leader ... to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel system ... provide visual documentation of monoclonality for use in cell line development. , ...
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... ... has announced the move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on ... SPIE to create an improved user experience and incorporate a number of enhancements ...
(Date:9/15/2017)... , ... September 15, 2017 , ... ... closed what it calls an ‘Internal Seed B’ round of financing, totaling $600,000. ... and was completed using a ‘SAFE’ documentation structure at a company valuation of ...
(Date:9/14/2017)... ... September 14, 2017 , ... Boston Strategic Partners, Inc. (BSP), ... Economics and Outcomes Research (HEOR) and ‘big data’ to provide in-depth analysis of ... spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
Breaking Biology News(10 mins):